13.22
前日終値:
$13.12
開ける:
$13.15
24時間の取引高:
75,933
Relative Volume:
0.88
時価総額:
$170.67M
収益:
$14.48M
当期純損益:
$-26.11M
株価収益率:
-5.8519
EPS:
-2.2591
ネットキャッシュフロー:
$-23.86M
1週間 パフォーマンス:
-2.88%
1か月 パフォーマンス:
-7.77%
6か月 パフォーマンス:
-26.30%
1年 パフォーマンス:
-24.27%
Mediwound Ltd Stock (MDWD) Company Profile
Compare MDWD vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
MDWD
Mediwound Ltd
|
13.22 | 175.45M | 14.48M | -26.11M | -23.86M | -2.2591 |
|
VRTX
Vertex Pharmaceuticals Inc
|
548.11 | 139.93B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
834.14 | 86.57B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
1,039.77 | 64.62B | 4.16B | 1.29B | 734.26M | 19.58 |
|
MRNA
Moderna Inc
|
145.07 | 69.62B | 2.23B | -3.19B | -1.60B | -8.1462 |
|
RVMD
Revolution Medicines Inc
|
209.48 | 46.01B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mediwound Ltd Stock (MDWD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-02 | 再開されました | Oppenheimer | Outperform |
| 2025-05-02 | 開始されました | Alliance Global Partners | Buy |
| 2025-02-28 | 開始されました | Craig Hallum | Buy |
| 2024-07-16 | 繰り返されました | Maxim Group | Buy |
| 2022-12-22 | 開始されました | Maxim Group | Buy |
| 2022-07-18 | 再開されました | Oppenheimer | Outperform |
| 2020-09-23 | 開始されました | BTIG Research | Buy |
| 2016-11-28 | 開始されました | Aegis Capital | Buy |
| 2016-08-17 | 開始されました | Wells Fargo | Outperform |
| 2014-04-16 | 開始されました | Oppenheimer | Outperform |
すべてを表示
Mediwound Ltd (MDWD) 最新ニュース
MediWound (MDWD) Q2 2026 Earnings Call Transcript - AOL.ca
MediWound (MDWD) Q2 2026 Results: The Bottom-Line Figure Outpaces Its Comparison in the Latest Session; Share-Price Check: Shares Move 1.87% Up on the DayNegative Surprise Momentum - dars.gov.et
What is HC Wainwright's Forecast for MediWound Q3 Earnings? - MarketBeat
Weekly Recap: Reaffirmed 2026 guidance and EscharEx Phase III enrollment - TradingView
MDWD Looks 30.8% Overvalued on GF Value™ - GuruFocus
Mediwound Ltd (MDWD) Stock News Today - TradingKey
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates - simplywall.st
MediWound Ltd. (NASDAQ:MDWD) Just Released Its Second-Quarter Earnings: Here's What Analysts Think - Moomoo
Maxim Group Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $30 - Moomoo
Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell - MarketBeat
MediWound (MDWD) Stock Faces Cash Burn As Revenue Slips - simplywall.st
MediWound Q2 2026 Earnings Call: Complete Transcript - Sahm
A Quick Look at Today's Ratings for MediWound(MDWD.US), With a Forecast Between $22 to $36 - Moomoo
MDWD Maintains by Oppenheimer -- Price Target Lowered to $30.00 - GuruFocus
T. Rowe Price Associates (MDWD) discloses 5.0% ownership in Mediwound common stock - Stock Titan
MediWound Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $36 - Moomoo
MediWound (MDWD) Earnings Call zu Q2 2026: VALU auf Kurs, Prognose bekräftigt - TradingKey
Key facts: MediWound Ltd. (MDWD) Q2 $3.09M rev; EscharEx $4B target - TradingView
Q2 2026 Mediwound Ltd Earnings Call Transcript - GuruFocus
Mediwound earnings missed by $0.03, revenue topped estimates - Investing.com Canada
MediWound (NASDAQ:MDWD) Issues Earnings Results - MarketBeat
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record - GuruFocus
MediWound Ltd (MDWD) (Q2 2026) Earnings Call Highlights: Record NexoBrid Sales and EscharEx ... - ca.finance.yahoo.com
A. G. P. Maintains MediWound(MDWD.US) With Buy Rating, Maintains Target Price $22 - Moomoo
MediWound Q2 2026 Earnings Call Transcript - MarketBeat
MediWound Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: MediWound tops Q2 2026 revenue forecast as shares rise - Investing.com
Mediwound Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
Mediwound Ltd. Reaffirms Revenue Guidance for the Full-Year 2026 - marketscreener.com
MediWound Q2 sales beat estimates; EPS miss widens as R&D rises - scanx.trade
MediWound Ltd. (MDWD) Q2 FY2026 earnings call transcript - Yahoo Finance
MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
MDWD: Q2 revenue fell, but guidance held as EscharEx and NexoBrid programs advanced and U.S. sales grew - TradingView
MediWound Q2 2026 Results Highlight EscharEx Trial Progress and New NexoBrid BARDA Agreement - TipRanks
MEDIWOUND ($MDWD) Releases Q2 2026 Earnings - Quiver Quantitative
MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
MediWound: Q2 Earnings Snapshot - Barchart.com
MDWD: Validated enzymatic therapies drive strong growth, targeting $1B+ peak sales in chronic wounds - TradingView
MediWound (NASDAQ: MDWD) revenue drops in H1 2026 but guidance held - Stock Titan
MediWound's Phase III Wound Trial Targets 216 Patients at About 40 Sites - Stock Titan
MediWound Q2 FY26 net loss narrows to USD 7.4 million; revenue drops to USD 3.1 million - Bitget
Technical Reactions to MDWD Trends in Macro Strategies - Stock Traders Daily
Mediwound Ltd expected to post a loss of 76 cents a shareEarnings Preview - TradingView
Mediwound Ltd (MDWD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MediWound (NASDAQ:MDWD) Stock Price Crosses Below 200-Day Moving AverageHere's What Happened - MarketBeat
MediWound (MDWD) Expected to Release Earnings on Thursday - MarketBeat
MediWound Ltd. Revenue Breakdown – FWB:M8W - TradingView
MDWD Q1 2026 Earnings: Narrower Loss of -$0.23 Per Share Beats Estimates by 65.57%Earnings Quality Analysis - Vinanet
Trading the Move, Not the Narrative: (MDWD) Edition - Stock Traders Daily
MDWD Q1 2026 Earnings: Significant EPS Beat Amidst Missing Revenue DataROA Comparison - Vinanet
Mediwound Ltd (MDWD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):